Skip to content
S2Medical

Healing Wounds. Fighting Resistance.

born in sweden, for the world.

ONE INNOVATION TAKEN TO GLOBAL STANDARD OF CARE · THE NEXT ONE IN DEVELOPMENT · NASDAQ FIRST NORTH: S2M

The technologyInvestor relations (SWE)
GÅ TILL: PRODUKTER OCH UPPHANDLINGAR I SVERIGE (SWE)

Innovation

Where ideas become the new standard

“Care without progress is not enough. Our mission is to replace wound care with wound healing.”

We believe the limits of today’s treatments should not define the possibilities of tomorrow. Our work starts by questioning what stands between a wound and healing, then developing products to address it.

With EPIPROTECT®, we took that approach from our lab into clinical practice. ABENA is expanding its reach through its wholly owned subsidiary EPIPROTECT AB, while royalties and market access bring ongoing value to S2Medical.

Admercin™ is our next chapter. Its patented peptides are designed to tackle antibiotic-resistant bacteria by disrupting their membranes. We are developing this technology into wound treatment products of our own, with the same ambition: to turn a scientific advance into a new standard of care.

EPIPROTECT®

From idea to global standard

S2Medical took EPIPROTECT from Swedish innovation, through clinical evidence, to global standard of care. That experience now informs the development of Admercin.

A complete concept

every step to healing

  1. 01 · Debridement

    Instaqrett®

    Preparing the wound: rapid removal of dead tissue, the first condition for healing.

    Read more

  2. 02 · Odour control

    NoSmell™ (Ynolens)

    Perfume-free odour control throughout the entire course of treatment.

    Read more

  3. 03 · Infection control

    Admercin™

    Under development

    Peptides that physically destroy resistant bacteria. No resistance observed over 20 generations in vitro. [2]

    Read more

All products

The antimicrobial peptide platform

evidence, not adjectives

“A soap that only washes away bacteria: and leaves human cells untouched.”

PURELY PHYSICAL MECHANISM: ACTIVITY RETAINED ACROSS ISOMERS AND FRAGMENTS [2]

>30×
Lower rifampicin dose in combination: in vitro [1]
0
Resistance after 20 generations of exposure: in vitro [1]
<10
CFU/g: S. aureus eradicated in porcine wound model [2]
9+
Peer-reviewed publications behind the platform

[1] Scientific Reports 2020;10:3580: co-authored by S2Medical founders · [2] Materials Today Bio 2025;32:101756

All publications

Epiprotect → Admercin

The dressing we took to global standard of care is now the delivery vehicle for our next platform.

Zattarin et al., Materials Today Bio 2025

In the preclinical porcine model, the EPIPROTECT dressing served as the delivery vehicle for the peptides: the dressing we took to global standard of care now carries our next platform.

2013
Founded in Linköping spin-off from Linköping University.
2018
Listed on Nasdaq First North Growth Market Stockholm, ticker S2M.
2020
First peer-reviewed proof the peptides make failing antibiotics work again (in vitro).
2024
EPIPROTECT® carried forward by ABENA through EPIPROTECT AB recurring revenue funds the next platform.
2025
The peptides eradicate wound infection in a preclinical model: delivered in the dressing we invented.
2026
Operating result turns positive in H1. The peptide platform advances.
Ticker
S2M
Market
Nasdaq First North GM
ISIN
SE0011725084
Investor relations (SWE)